Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®

by Ysios Capital

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC

Read more

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

by Ysios Capital

Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company CVRx Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq Glob...

Read more

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

by Ysios Capital

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

ORYZON presents preliminary data from on...

by Oryzon Genomics

Data from the first two cohorts demonstrated that combination of iadad...

Photos Stream